Advertisement
EBS vs QNTM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and QNTM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 1 FA rating(s) are green whileQNTM’s FA Score has 0 green FA rating(s).
- EBS’s FA Score: 1 green, 4 red.
- QNTM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 4 TA indicator(s) are bullish while QNTM’s TA Score has 2 bullish TA indicator(s).
- EBS’s TA Score: 4 bullish, 4 bearish.
- QNTM’s TA Score: 2 bullish, 4 bearish.
Price Growth
EBS (@Pharmaceuticals: Other) experienced а +8.24% price change this week, while QNTM (@Biotechnology) price change was -30.02% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +113.87%. For the same industry, the average monthly price growth was +74.83%, and the average quarterly price growth was +80.55%.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.46%. For the same industry, the average monthly price growth was +36.24%, and the average quarterly price growth was +15.15%.
Reported Earning Dates
EBS is expected to report earnings on Aug 12, 2025.
QNTM is expected to report earnings on Mar 28, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+113.87% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (+8.46% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| EBS | QNTM | EBS / QNTM | |
| Capitalization | 120M | 60.7M | 198% |
| EBITDA | -518.2M | -20.68M | 2,506% |
| Gain YTD | -28.556 | 473.913 | -6% |
| P/E Ratio | 17.73 | N/A | - |
| Revenue | 1.02B | 0 | - |
| Total Cash | 112M | 3.54M | 3,165% |
| Total Debt | 860M | 1.28M | 67,188% |
EBS | QNTM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 34 | |
P/E GROWTH RATING 1..100 | 11 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (57) in the Biotechnology industry is in the same range as QNTM (72) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as QNTM (100) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
EBS's SMR Rating (94) in the Biotechnology industry is in the same range as QNTM (100) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
QNTM's Price Growth Rating (34) in the null industry is in the same range as EBS (47) in the Biotechnology industry. This means that QNTM’s stock grew similarly to EBS’s over the last 12 months.
EBS's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for QNTM (100) in the null industry. This means that EBS’s stock grew significantly faster than QNTM’s over the last 12 months.
| EBS | QNTM | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 83% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 73% | N/A |
| MACD ODDS (%) | 2 days ago 77% | N/A |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 75% |
| Advances ODDS (%) | 5 days ago 77% | 8 days ago 83% |
| Declines ODDS (%) | 11 days ago 89% | 2 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 77% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| KLCAX | 17.52 | N/A | N/A |
| Federated Hermes Kaufmann Large Cap A | |||
| NSNCX | 45.87 | N/A | N/A |
| Neuberger Berman Small Cap Growth C | |||
| DFWIX | 15.23 | N/A | N/A |
| DFA World ex US Core Equity Instl | |||
| ECEIX | 11.88 | N/A | N/A |
| Lazard Emerging Markets Core Equity Inst | |||
| WWMCX | 11.31 | N/A | N/A |
| Westwood Quality Midcap Institutional | |||
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with HROW. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then HROW could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | +0.89% | ||
| HROW - EBS | 39% Loosely correlated | -0.63% | ||
| AMRX - EBS | 37% Loosely correlated | +0.99% | ||
| SIGA - EBS | 34% Loosely correlated | +1.86% | ||
| VTRS - EBS | 30% Poorly correlated | +2.59% | ||
| ANIP - EBS | 30% Poorly correlated | -0.15% | ||
More | ||||
QNTM and
Correlation & Price change
A.I.dvisor tells us that QNTM and CPIX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QNTM and CPIX's prices will move in lockstep.
| Ticker / NAME | Correlation To QNTM | 1D Price Change % | ||
|---|---|---|---|---|
| QNTM | 100% | -13.34% | ||
| CPIX - QNTM | 26% Poorly correlated | +5.10% | ||
| EBS - QNTM | 24% Poorly correlated | +0.89% | ||
| RNA - QNTM | 24% Poorly correlated | -0.23% | ||
| PBH - QNTM | 24% Poorly correlated | -0.72% | ||
| ATAI - QNTM | 23% Poorly correlated | +2.27% | ||
More | ||||